A growing body of research points to the role of the gut-brain axis in the development of Parkinson disease, with inflammatory bowel disease, leaky gut, and altered gut microbiota observed in the gut, often years before the onset of symptoms of Parkinson disease.
Compared with their peers, Asian patients with dementia were less likely to be prescribed antidementia drugs, and they received these drugs for fewer days per year.
The presence of objective subtle cognitive difficulties (Obj-SCD) on neuropsychological measures may predict faster amyloid accumulation and neurogenerative changes.
The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.
Survey data published in JAMA Neurology indicate that approximately half of US adults perceive themselves to be at least somewhat likely to develop dementia.
Behavioral variant frontotemporal dementia, a neurodegenerative disease that affects the frontal and anterior temporal lobes, results in disordered socioemotional behavior.
Alzheimer disease patients who initiate treatment with antipsychotic medications spend more days hospitalized than those who do not initiate antipsychotics.
